



<b>Title</b>	<b>The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development</b>
<b>Author(s)</b>	<b>Zhang, Y; Yuan, T; Li, J; Zhang, Y; Xu, J; Shao, Y; Chen, Z; Zhang, M</b>
<b>Citation</b>	<b>AIDS, 2013, v. 27 n. 16, p. 2529-2539</b>
<b>Issued Date</b>	<b>2013</b>
<b>URL</b>	<b><a href="http://hdl.handle.net/10722/185535">http://hdl.handle.net/10722/185535</a></b>
<b>Rights</b>	<b>This is a non-final version of an article published in final form in AIDS, 2013, v. 27 n. 16, p. 2529-2539</b>

**The potential of the human immune system to develop broadly neutralizing HIV-1  
antibodies: implications for vaccine development**

**Yu Zhang<sup>a</sup>, Tingting Yuan<sup>a</sup>, Jingjing Li<sup>a</sup>, Yanyu Zhang<sup>a</sup>, Jianqing Xu<sup>b</sup>, Yiming Shao<sup>c</sup>,  
Zhiwei Chen<sup>a</sup>, and Mei-Yun Zhang<sup>a,1</sup>**

<sup>a</sup>AIDS Institute, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

<sup>b</sup>Institutes of Biomedical Sciences, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China

<sup>c</sup>Division of Research on Virology and Immunology, National Center for AIDS/STD Control and Prevention, China CDC, Beijing 102206, China

Running title: human genomic DNA antibody repertoires

**<sup>1</sup>To whom correspondence should be addressed:**

**Mei-Yun Zhang, PhD**, AIDS Institute, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong. L5-45, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong, China. Phone: 852-28183685; Fax: 852-28177805; Email: [zhangmy@hku.hk](mailto:zhangmy@hku.hk)

**Abbreviations:** gDNA, genomic DNA; VHs and VKs/VLs, antibody heavy and kappa and lambda light chain variable regions; IGHVs and IGKVs/IGLVs, immunoglobulin heavy and kappa and lambda light chain V-genes; CDR3, the third complementarity-determining region; PBMCs, peripheral blood mononuclear cells.

## **Abstract**

**Objectives and Design:** Developing an effective HIV-1 vaccine that elicits broadly neutralizing HIV-1 human antibodies (bnAbs) remains a challenging goal. Extensive studies on HIV-1 have revealed various strategies employed by the virus to escape host immune surveillance. Here we investigated the human antibody gene repertoires of uninfected and HIV-1-infected subjects at genomic DNA (gDNA) and cDNA levels by deep sequencing followed by high-throughput sequence analysis to determine the frequencies of putative germline antibody genes of known HIV-1 monoclonal bnAbs (bnmAbs).

**Methods:** Combinatorial gDNA and cDNA antibody libraries were constructed using the gDNAs and mRNAs isolated from uninfected and HIV-1-infected human PBMCs. All libraries were deep sequenced and sequences analyzed using IMGT/HighV-QUEST software (<http://imgt.org/HighV-QUEST/index.action>). The frequencies of putative germline antibodies of known bnmAbs in the gDNA and cDNA libraries were determined.

**Results and Conclusion:** The human gDNA antibody libraries were more diverse in heavy and light chain V-gene lineage usage than the cDNA libraries, indicating that the human gDNA antibody gene repertoires may have more potential than the cDNA repertoires to develop HIV-1 bnAbs. The frequencies of the heavy and kappa and lambda light chain variable regions (VHs and VKs/VLs) with identical V(D)J recombinations to known HIV-1 bnmAbs were extremely low in human antibody gene repertoires. However, we found relatively high frequencies of the VHs and VKs/VLs that used the same V-genes and had the same CDR3 length as known HIV-1 bnmAbs regardless of (D)J-gene usage. B-cells bearing B-cell receptors of such VHs and VKs/VLs may be stimulated to induce HIV-1 bnAbs.

**Keywords:** HIV-1, neutralizing antibodies, germline antibodies, genomic DNA, cDNA, antibody somatic maturation

## **Introduction**

Since the discovery of HIV-1 in the early 1980's, an effective HIV-1 vaccine that can elicit bnAbs has yet to be developed. Extensive studies on HIV-1 have revealed various mechanisms for viral escape from human immune surveillance, including genetic alterations, oligomerization of envelope (Env) glycoproteins, heavy glycosylation, and conformational masking [1-7]. But little is known about the potential of the human immune system to develop HIV-1 bnAbs. About 10-30% HIV-1-infected subjects develop cross-clade neutralizing Abs in natural infection, but only 1-3% subjects develop high titers of potent bnAbs after years of chronic infection. Enormous efforts have been made to isolate bnmAbs from HIV-1-infected “elite controllers” whose sera exhibit high titers of broad neutralization activity. Four well-known bnmAbs, b12, 2G12, 2F5 and 4E10, were identified more than a decade ago [8-11]. Many new and more potent bnmAbs were reported in the past three years, including PG9/16, HJ16, VRC01-03, VRC01-like Abs, PGTs and 10e8 [12-19]. Approximately twelve bnmAbs have been co-crystallized with Env and their neutralizing epitopes determined [18, 20-26]. However, immunogens designed to include the neutralizing determinants of several HIV-1 bnmAbs have not been successful in inducing the same or similar bnAbs.

We and others have demonstrated that known HIV-1 bnmAbs had uncommon properties compared to bnmAbs against other microbes, including extensive somatic maturation and lack of measurable binding activity of their putative germline antibodies to Envs [13, 15, 16, 18, 27, 28], suggesting that HIV-1 infection or vaccination with HIV-1 Envs may not initiate the somatic maturation processes of the putative germline Abs to bnAbs. Deep sequencing of the cDNA-PCR products of memory B cells obtained from several “elite controllers” at different time points post-infection further revealed the limited use of heavy chain V-gene (IGHV) lineages for

developing HIV-1 bnAbs in a single infected subject [17, 18, 29]. The infrequency of developing bnAbs in natural infection, the uncommon properties of known HIV-1 bnAbs, the confined usage of IGHV lineages for developing bnAbs in a single infected subject, and the failure in inducing the same or similar bnAbs by vaccine immunogens prompted us to investigate the human antibody gene repertoire for the availability of the putative germline antibody genes of known HIV-1 bnAbs at both genomic DNA (gDNA) and cDNA levels and the possibility for existence of alternative germline antibody genes that may potentially mature to HIV-1 bnAbs. The gDNAs of peripheral B cells in uninfected human subjects presumably possess the initial rearranged antibody gene repertoire for affinity maturation upon infection or vaccination. We hypothesized that antibody gene repertoire at the gDNA level may be more diverse than that at the cDNA level. Therefore, we developed a methodology for constructing large combinatorial gDNA antibody libraries and constructed one large nonimmune gDNA library using the PMBCs obtained from 300 uninfected healthy humans and three immune gDNA libraries using the PMBCs obtained from three HIV-1-infected “elite controllers”. Their corresponding cDNA libraries were simultaneously constructed. We compared the antibody gene repertoires of the four gDNA antibody libraries with those of the corresponding cDNA libraries by deep sequencing. Sequence analysis results suggest that the frequencies of the putative germline antibody genes of known HIV-1 bnAbs were extremely low, but alternative germline antibody genes may be explored to elicit HIV-1 bnAbs.

## **Materials and methods**

### *Preparation of human PMBCs*

The PBMCs of healthy volunteers were obtained from The University of Hong Kong (Hong Kong, China). PBMCs from patient 1 (pt1) were obtained from Aaron Diamond AIDS Research Center, Rockefeller University (New York, USA). PBMCs from patient 2 and 3 (pt2 and pt3) were obtained from National Center for AIDS/STD Control and Prevention, China CDC (Beijing, China). All these experiments were approved by ethical committees of the respective institutes, and conducted according to local guidelines and regulations. All three patients were elite controllers. Pt1 was infected with clade B virus whose serum exhibited high titers of broadly neutralizing activity, and a panel of bnmAbs were isolated from pt1 PBMCs by single memory cell sorting using gp120 C-C core protein as a bait [pt1 in [18, 28]]. Pt2 and pt3 were infected with clade B' virus and naive to antiretroviral therapy [30]. The sera of pt2 and pt3 also exhibited cross-clade neutralization activity (data not shown). Heparinized whole blood samples were used to isolate human PBMCs by Ficoll density gradient separation.

#### *Isolation of gDNA, total RNA and mRNA from human PBMCs*

Five to ten million PBMCs were collected from each 5 mL of heparinized whole blood and were used to isolate gDNA and total RNA using Allprep DNA/RNA Mini kits (Qiagen) following the protocol provided by the manufacturer. The gDNA was used as a template for amplification of heavy chain variable regions (VHs) and kappa and lambda light chain variable regions (VKs/VLs) by semi-nested PCR for construction of gDNA antibody single chain antibody fragment (scFv) libraries in phagemid vector pComb3X. Total RNA from uninfected individual PBMCs were pooled and mRNA was prepared from the pooled total RNA using the “Oligotex mRNA Mini Kit” (Qiagen). The mRNA was used to reverse transcribe cDNA for construction of cDNA antibody libraries.

### *Construction of gDNA antibody scFv libraries*

A total of 67 primers were designed and used in semi-nested PCR reactions to amplify VHs and VKs/VLs using gDNA as a template, and in SOE-PCR to assemble scFvs for gDNA scFv library construction (Table S1). Reverse primers were mixed at equal molar concentrations prior to semi-nested PCR. Each sense primer annealing to leader sequences or framework 1 (FR1) regions of VHs or VKs/VLs was paired with the corresponding mixed anti-sense primers and used at the same final concentration (10  $\mu$ M) in the 1<sup>st</sup> or 2<sup>nd</sup> round of PCRs. Each 1<sup>st</sup> round of PCR was carried out in a reaction volume of 100  $\mu$ L containing 90 ng gDNA as a template by running the following PCR program: initial denaturing at 95°C for 3 min, 10 cycles of 95°C for 15 sec, 45°C for 30 sec, 72°C for 45 sec, 20 cycles of 95°C for 15 sec, 55°C for 30 sec, 72°C for 45 sec, and an extension cycle of 72°C for 10 min. The 2<sup>nd</sup> round of PCR was carried out using the corresponding 1<sup>st</sup> round PCR product as a template and running the following PCR program: initial denaturing at 95°C for 3 min, 30 cycles of 95°C for 15 sec, 55°C for 30 sec, 72°C for 30 sec and an extension cycle of 72°C for 10 min. Semi-nested PCR products were gel-purified using a QIAquick gel extraction kit (Qiagen). The purified VHs and VKs/VLs were then covalently linked by a flexible (G4S)<sub>3</sub> linker by SOE-PCR to assemble scFvs using the primer pairs Sfi5new/LINKR and LINKF/Sfi3hisR. The SOE-PCR products were gel-extracted, digested with SfiI and ligated to pComb3X. The ligated products were then electroporated into TG1 electrocompetent cells.

### *Construction of cDNA antibody Fab libraries*



The pooled mRNA from the healthy donors' PBMCs and the mRNA from three elite controllers were used to reverse transcribe cDNA by using the "SuperScript III cDNA Synthesis Kit". The cDNA was used as a template to amplify VHs and kappa/lambda light chains (LCs) by PCR using high-fidelity DNA polymerase and primers annealing to FR1s and FR4s of human antibody heavy chain variable regions and primers annealing to FR1s and constant regions of human antibody light chains (Table S2). The human antibody heavy chain first constant domain (CH1) sequence was then attached to the VHs by SOE-PCR to assemble Fds. LCs and Fds were further assembled by SOE-PCR to obtain Fab fragments. The Fab fragments were then ligated to pComb3X, and ligated products electroporated into TG1 electrocompetent cells.

#### *Deep sequencing and sequence analysis*

Primers annealing to pComb3X vector or heavy and light chain constant regions (Table S1 and S2) were used to amplify the scFvs from the gDNA antibody libraries and Fds and LCs from the cDNA antibody libraries. Gel-purified PCR products were sent for deep sequencing using the Roche 454 genome sequencer (GS) FLX. Trim sequences ( $\geq 290$  nt) were analyzed using IMGT/HighV-QUEST software (<http://imgt.org/HighV-QUEST/index.action>).

## **Results**

#### *Construction of large combinatorial DNA and cDNA antibody libraries*

We prepared the gDNAs from the PBMCs of 300 uninfected healthy donors and amplified the VHs and VKs/VLs by semi-nested PCR using pooled gDNA as a template and a set of primers that annealed to the leader sequence or framework 1 (FR1) or FR4 of each VH or VK/VL family (Table S1). The VHs and VKs/VLs were then covalently linked by a flexible (G4S)<sub>3</sub> linker by

strand overlap extension (SOE)-PCR to assemble scFvs. The resultant combinatorial gDNA scFv library, including two sub-libraries, designated NIgH/gK and NIgH/gL, in pComb3X contained over 600 million individual clones. Similarly, we constructed three immune gDNA scFv libraries using the gDNAs isolated from pt1, pt2 and pt3. Each immune gDNA scFv library had kappa and lambda sub-libraries except that pt1 lambda sub-library was omitted. Five sub-libraries were designated pt1gH/gK, pt2gH/gK, pt2gH/gL, pt3gH/gK and pt3gH/gL, and each sub-library contained 1-6 billion individual clones. We simultaneously constructed corresponding combinatorial cDNA antibody Fab libraries except that construction of a cDNA Fab library using pt1 PBMCs was omitted because the isolation of bnmAbs by single cell sorting of memory B-cells from pt1 PBMCs has been reported [18, 28]. The resultant nonimmune and immune cDNA Fab kappa and lambda sub-libraries were designated NIH/NIK and NIH/NIL, pt2H/pt2K and pt2H/pt2L, and pt3H/pt3K and pt3H/pt3L, respectively. Each sub-library contained 1-6 billion individual clones.

*More diverse IGHV lineage usage in the gDNA libraries than in the cDNA libraries*

We amplified the scFvs from the gDNA libraries and the Fds and LCs from the cDNA libraries using primers that annealed to the pComb3X vector or to the constant regions of heavy or light chains (CH1 and CL, respectively) (Table S1 and S2) and sent the PCR products for deep sequencing. We obtained trim sequences (>290nt) from each library ranging from 23,530 to 88,331 for VHs, and from 17,285 to 28,110 for VKs and from 21,480 to 30,199 for VLs. Sequence analysis showed different patterns of using various IGHV and IGKV/IGLV (kappa and lambda light chain V-genes) lineages in different gDNA and cDNA libraries, and the differences between the gDNA and corresponding cDNA libraries were more significant than those between

the nonimmune and immune gDNA or cDNA libraries (Fig. 1-3). The gDNA libraries were more diverse overall than the cDNA libraries in using various IGHV lineages (Fig. 1 and 2). Among the four gDNA heavy chain libraries, NIgH and pt1gH showed a similar pattern of various IGHV lineage usage, while pt2gH and pt3gH were significantly different from NIgH and pt1gH in using IGHV1, 2 and 6 lineages (Fig. 1 and 2). Compared to the gDNA heavy chain libraries, the corresponding cDNA heavy chain libraries had significantly higher percentages of clones using IGHV1 and IGHV3 lineages (Fig. 1), and were biased to certain VH1 and VH3 subfamilies, including IGHV1-18, 1-2 and 1-69, and IGHV 3-11, 3-21, 3-23, 3-30, 3-33, 3-49, 3-7 and 3-74 (Fig. 2). The patterns of various IGKV/IGLV lineage usages in the nonimmune and immune gDNA libraries were similar except for pt1gK library (Fig. 1 and 3). The nonimmune and immune cDNA libraries also showed a similar pattern in using various IGKV/IGLV lineages. Both nonimmune and immune cDNA antibody libraries heavily used IGKV3 and IGLV1 lineages (Fig. 1 and 3). These results indicate that HIV-1 infection shapes the patterns of various IGHV lineage usages, but the caused changes at the cDNA level are much less significant compared to the changes at the gDNA level. The differences between the gDNA and cDNA antibody gene repertoires in HIV-1 uninfected (nonimmune) humans reflect host immune regulations, and such regulations may largely determine the host-dependent immune response to HIV-1 infection.

*Extremely low frequency of the VHs and VKs/VLs with identical V(D)J recombinations to known HIV-1 bnmAbs*

To investigate the potential of basal human antibody gene repertoires to develop HIV-1 bnAbs, we analyzed the trim VH sequences and counted the number of VHs that had identical putative

VDJ recombinations to five known CD4bs bnmAbs b12, VRC01, VRC03, NIH45-46 and 3BNC60, and two glycan- and loop-specific bnmAbs PG9 and pGT127. To our surprise, we found that the frequencies of the VHs with identical putative VDJ recombinations to these known HIV-1 bnmAbs in both nonimmune and immune gDNA and cDNA libraries were extremely low (Table 1). We did not find any VHs that had identical VDJ recombinations compared to the known bnmAbs in the nonimmune and three immune gDNA libraries (Table 1). We found a total of 5, 10 and 2 productive VHs (with in-frame junctions) in the cDNA libraries with exactly the same putative VDJ recombinations as VRC01, VRC03 and NIH45-46, respectively (Table 1). However, their junction regions and the length of the HCDR3s were very different compared to the respective bnmAbs (data not shown), suggesting the unlikelihood for them to mature to VRC01-like bnAbs. We did a similar search for VHs that had identical VDJ recombinations to a non-neutralizing or weakly neutralizing CD4-induced (CD4i) mAb X5 and a bnmAb against SARS-CoV, m396 [31, 32]. We found 4 productive VHs in two immune gDNA libraries (1 in pt2gH and 3 in pt3gH) and a total of 28 productive VHs in the cDNA libraries (12 in NIH, 2 in pt2H, and 14 in pt3H) that had identical putative VDJ recombinations to X5, but all these VHs had a shorter HCDR3 than that of X5 (24 amino acids, AA). We found 1 VH in pt1gH library and 1 VH in NIH library that had exactly the same putative VDJ recombination as m396, but none of them had the same HCDR3 length as that of m396 (11AA). These results indicate that the chance of having a VH with a defined VDJ recombination along with a specific HCDR3 length could be extremely low in human antibody gene repertoires.

The frequencies of the VKs that had the identical VJ recombinations to the known HIV-1 bnmAbs in both nonimmune and immune gDNA and cDNA libraries were also very low except that the frequencies of the VKs with the identical VJ recombination to b12 VK (IGKV3-20 /

IGKJ2) were relatively high (Table 1). X5 used the same VJ recombination as b12, so the frequencies of the VKs with identical VJ recombination to X5 were also relatively high. Interestingly, we found that the frequencies of the VLs with the identical VJ recombinations to bnmAbs PG9 and PGT127 were also relatively high, while the frequencies of the VLs with the identical VJ recombination to m396 were very low (Table 1).

*Relatively high frequencies of VHs and VKs/VLs that used the same or very similar IGHVs and IGKVs/IGLVs and had the same length of CDR3s as known HIV-1 bnmAbs regardless of (D)J-gene usage*

It is usually difficult to determine which D- and J-genes were recombined with the V-genes to generate VHs, owing to the complexity of VDJ recombination events. Therefore, we searched for productive VHs that used the same or very similar IGHVs and had the same length of HCDR3 as known HIV-1 bnmAbs regardless of D- and J-gene usage. The frequencies of such VHs were relatively high in the nonimmune and immune gDNA and cDNA libraries compared to the frequencies of the VHs with exactly the same VDJ recombinations of known HIV-1 bnmAbs except for VRC03, PG9 and PGT127 that had long HCDR3s (23, 30 and 25 AA, respectively) (Table 2). X5 also had a long HCDR3 (24 AA), so the frequencies of the VHs that used the same or very similar IGHV of X5 and had the same HCDR3 length were not higher than the frequencies of the VHs with exactly the same VDJ recombinations of X5. Similar analysis of trim VKs/VLs also showed relatively high frequencies of the VKs/VLs that used the same or very similar IGKVs/IGLVs and had the same length of CDR3 as known HIV-1 bnmAbs regardless of J-gene usage, especially for b12, PG9 and PGT127 (Table 2).

## Discussion

B-cell antigen receptors (BCRs) develop as B-cells differentiate. VDJ recombination for the heavy chain and VJ recombination for the light chain occur sequentially at pro-B and pre-B stages, respectively, in the bone marrow. Immature B-cells exit the bone marrow and enter the peripheral system where new emigrant B cells differentiate into immature then mature naïve B-cells. Mature B-cells undergo somatic maturation upon immunogen stimulation and differentiate into Ab-secreting plasma cells or memory B-cells. Thus, the peripheral blood contains a population of B-cells that have undergone V(D)J recombinations, and the gDNAs of peripheral B-cells of nonimmune human subjects possess the basal rearranged antibody gene repertoire for antibody affinity maturation. The genome-based antibody gene repertoire may differ from the cDNA-based antibody gene repertoire owing to the different transcriptional and / or translational levels of different antibody genes, and both repertoires may be shaped upon viral infection or vaccination. Therefore, we constructed a large combinatorial nonimmune and three immune human gDNA antibody libraries and their corresponding cDNA antibody libraries for comparison of antibody gene repertoires at the gDNA and cDNA levels by deep sequencing and for subsequent isolation of Env-specific germline or intermediate antibodies (with low level of somatic maturation) by phage display. We found that frequencies of the VHs and VKs/VLs with identical putative V(D)J recombinations to known HIV-1 bnMAbs were extremely low in both nonimmune gDNA and cDNA libraries, suggesting that known HIV-1 bnMAbs may not be derived from the putative germline antibodies, or the chance for such direct maturation may be very low. If a certain combination of putative germline heavy and light chains is required for HIV-1 bnAbs, the frequency of such germline antibody genes may be even lower. Compared to the lack of measurable binding of putative germline antibodies of known HIV-1 bnMAbs to Env

and the requirement of extensive somatic maturation for broadly neutralizing activity [13, 27], limited availability of B-cells bearing proper germline antibody genes that may mature to HIV-1 bnAbs upon stimulation may be a formidable challenge for developing an effective HIV-1 vaccine. The extremely low frequency of the putative germline antibody genes of known HIV-1 bnmAbs in the human antibody gene repertoires suggests that the approach for eliciting HIV-1 bnAbs by identifying primary immunogens to trigger the putative germline antibodies of known HIV-1 bnmAbs in vivo may have a very limited chance of success. However, our further sequence analyses revealed relatively high frequencies of the VHs and VKs/VLs in the human antibody gene repertoires that use the same or very similar IGHVs and IGKVs/IGLVs and have the same CDR3 length as known HIV-1 bnmAbs regardless of (D)J-gene usage. B-cells harboring such VHs and VKs/VLs may be stimulated to induce bnAbs. Note that we used the plasmids from the cDNA Fab libraries and the gDNA scFv libraries as templates for PCR amplification of the VHs and VKs/VLs for deep sequencing. The cDNA Fab libraries were constructed earlier and used in our previous studies. We did not convert the Fab libraries to scFv libraries because it was not necessary to do so. Conversion between two different formats of antibody libraries may cause loss of antibody diversity and result in bias to certain antibody gene families.

Exploring the human gDNA antibody gene repertoire may be another approach for eliciting HIV-1 bnAbs. As we hypothesized, the gDNA antibody gene repertoires showed more diverse usages of IGHV lineages than the cDNA repertoires. Indeed, we have isolated a panel of RSC3-specific antibodies from our combinatorial gDNA libraries, but not from the cDNA libraries (manuscript in preparation). The isolated RSC3-specific antibodies had no or very low levels of somatic maturation and used diverse V(D)J recombinations, but they competed with mature b12

and VRC01 for binding to engineered Env, RSC3 [13], suggesting their potential to mature to VRC01-like bnAbs. We are currently doing in vitro maturation and selection to confirm that they can potentially mature to VRC01-like bnAbs.

We obtained 33,436 and 80,331 trim VH sequences from 454 deep sequences of the nonimmune gDNA and cDNA libraries, respectively (Table 1 and 2), which were comparable to the theoretical maximum diversity of the basal human VH gene repertoire ( $3.1 \times 10^4$ ). The unequal usage of IGHV, IGHD and IGHJ genes in the nonimmune gDNA library suggests that VDJ recombination may not be a random event. The differences may be amplified by host immune regulations to remove or functionally silence B-cells expressing autoimmune antibodies or to deplete the B-cells that recognize B-cell superantigens [33-35]. This could lead to a different frequency of various germline antibody genes in the initial antibody gene repertoire for affinity maturation. For example, the VHs using IGHV1-2 or with HCDR3s of long length (20 AA and over) were significantly less frequent than the VHs using IGHV1-46 or with HCDR3s of medium length (10-15 AA) (Fig. 2 and data not shown). Arnaout et al. also showed that V, D, and J segments were utilized with different frequencies, resulting in a highly skewed representation of VDJ combinations in the human antibody gene repertoire [36]. However, they found that the pattern of segment usage was almost identical between two different individuals. Our result seems different from their finding. We found that IGHV lineage usage differs from individual to individual. In addition, they reported that IGHV1-2 lineage accounted for 2-3% sequence in non-immune human antibody gene repertoire [36]. We found a similar percentage in our cDNA libraries, but the percentages of IGHV1-2 lineage in gDNA libraries were 10-100-fold lower (Fig. 2). The more diverse usages of IGHV lineages may account for this phenomenon.



Our study suggests the potential of the human immune system to develop HIV-1 bnAbs, which may have implications for vaccine development. In addition to searching for proper germline antibodies as targets for vaccine immunogen design, immune modulations may be required to tackle possible obstacles posed by the host and/or the virus to affinity maturation to HIV-1 bnAbs.

### **Acknowledgements**

We wish to thank David D. Ho for the patient 1 sample, Zhi-Yong Yang, Tongqing Zhou and Peter D. Kwong for RSC3 and  $\Delta$ RSC3 proteins, Xueling Wu and John R. Mascola for VRC01 antibody, Dennis R. Burton for the pComb3X plasmid, Peter D. Kwong, John R. Mascola, Tongqing Zhou, Xueling Wu, and Dimitar S. Dimitrov for helpful discussions, and Jenny Ng for editing the manuscript. **Author contributions:** M-Y. Z. designed research; Y.Z., T.Y., J.L. Y.Z. and M-Y. Z. performed research; Y.Z., Y.Z., and M-Y.Z. analyzed data; Z.C. and Y.S. contributed patient samples; and M-Y.Z. and J.X. wrote the paper. **Funding:** This work was supported by Hong Kong Research Grants Councils (RGC) General Research Fund (GRF) (#785210 and #785112) and China 12<sup>th</sup> 5-year Mega project for HIV/AIDS (#2012ZX10001006) to M-Y.Z. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### **Figure legend**

**Fig. 1 Percentage of VH and VK/VL family in nonimmune and immune gDNA and cDNA antibody libraries.** NIgH/K/L: nonimmune gDNA scFv library; NIH/K/L: nonimmune cDNA

Fab library; pt1-3gH/K/L: patient gDNA scFv library; pt1-3H/K/L: patient cDNA Fab library.

Note: pt1gL library is not available.

**Fig. 2 Percentage of IGHV lineages in the nonimmune and immune gDNA and cDNA**

**libraries.** NIgH: nonimmune gDNA scFv library; NIH: nonimmune cDNA Fab library; pt1-3gH: patient gDNA scFv library; pt1-3H: patient cDNA Fab library.

**Fig. 3 Percentage of IGKV/IGLV lineages in the nonimmune and immune gDNA and**


**cDNA libraries.** NIgK/L: nonimmune gDNA scFv library; NIK/L: nonimmune cDNA Fab library; pt1-3gK/L: patient gDNA scFv library; pt1-3K/L: patient cDNA Fab library.

**References**


1. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. *Nature* 1998,**393**:648-659.
2. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, *et al.* The antigenic structure of the HIV gp120 envelope glycoprotein. *Nature* 1998,**393**:705-711.
3. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. *J Virol* 2000,**74**:1961-1972.
4. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, *et al.* HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. *Nature* 2002,**420**:678-682.
5. Shaw GM, Hahn BH, Arya SK, Groopman JE, Gallo RC, Wong-Staal F. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. *Science* 1984,**226**:1165-1171.
6. Hahn BH, Gonda MA, Shaw GM, Popovic M, Hoxie JA, Gallo RC, *et al.* Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. *Proc Natl Acad Sci U S A* 1985,**82**:4813-4817.
7. Wong-Staal F, Shaw GM, Hahn BH, Salahuddin SZ, Popovic M, Markham P, *et al.* Genomic diversity of human T-lymphotropic virus type III (HTLV-III). *Science* 1985,**229**:759-762.
8. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, *et al.* Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. *Science* 1994,**266**:1024-1027.
9. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, *et al.* A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. *AIDS Res Hum Retroviruses* 1994,**10**:1651-1658.
10. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, *et al.* The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. *J Virol* 2002,**76**:7306-7321.

11. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, *et al.* A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. *AIDS Res Hum Retroviruses* 2001,**17**:1757-1765.
12. Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E, *et al.* A method for identification of HIV gp140 binding memory B cells in human blood. *J Immunol Methods* 2009,**343**:65-67.
13. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, *et al.* Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. *Science* 2010,**329**:856-861.
14. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, *et al.* Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. *PLoS ONE* 2010,**5**:e8805.
15. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, *et al.* Broad neutralization coverage of HIV by multiple highly potent antibodies. *Nature* 2011,**477**:466-470.
16. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, *et al.* Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. *Science* 2009,**326**:285-289.
17. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, *et al.* Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. *Science* 2011,**333**:1593-1602.
18. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, *et al.* Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. *Science* 2011,**333**:1633-1637.
19. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, *et al.* Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. *Nature* 2012,**491**:406-412.
20. Calarese DA, Lee HK, Huang CY, Best MD, Astronomo RD, Stanfield RL, *et al.* Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. *Proc Natl Acad Sci U S A* 2005,**102**:13372-13377.
21. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, *et al.* Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. *Nature* 2011,**480**:336-343.
22. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, Schmidt SD, *et al.* Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. *J Virol* 2010,**84**:8098-8110.
23. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, *et al.* A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. *Science* 2011,**334**:1097-1103.
24. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, *et al.* Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. *Science* 2001,**293**:1155-1159.
25. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, *et al.* Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. *Science* 2010,**329**:811-817.
26. Zhou T, Xu L, Dey B, Hessel AJ, Van Ryk D, Xiang SH, *et al.* Structural definition of a conserved neutralization epitope on HIV-1 gp120. *Nature* 2007,**445**:732-737.
27. Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, Wang Y, *et al.* Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. *Biochem Biophys Res Commun* 2009,**390**:404-409.

28. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, *et al.* Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. *Nature* 2009,**458**:636-640.
29. Bonsignori M, Montefiori DC, Wu X, Chen X, Hwang KK, Tsao CY, *et al.* Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. *J Virol* 2012,**86**:4688-4692.
30. Hu X, Hong K, Zhao C, Zheng Y, Ma L, Ruan Y, *et al.* Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy. *J Gen Virol* 2012,**93**:2267-2278.
31. Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, *et al.* Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. *Proc Natl Acad Sci U S A* 2007,**104**:12123-12128.
32. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, *et al.* Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. *Proc Natl Acad Sci U S A* 2002,**99**:6913-6918.
33. Zouali M. B cell superantigens subvert innate functions of B cells. *Chem Immunol Allergy* 2007,**93**:92-105.
34. Paul S, Planque SA, Nishiyama Y, Hanson CV, Massey RJ. Nature and nurture of catalytic antibodies. *Adv Exp Med Biol* 2012,**750**:56-75.
35. Planque SA, Mitsuda Y, Nishiyama Y, Karle S, Boivin S, Salas M, *et al.* Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine. *J Immunol* 2012,**189**:5367-5381.
36. Arnaout R, Lee W, Cahill P, Honan T, Sparrow T, Weiland M, *et al.* High-resolution description of antibody heavy-chain repertoires in humans. *PLoS ONE* 2011,**6**:e22365.



**Fig. 1 Percentage of VH and VK/VL family in nonimmune and immune gDNA and cDNA antibody libraries.** NIgH/K/L: nonimmune gDNA scFv library; NIH/K/L: nonimmune cDNA Fab library; pt1-3gH/K/L: patient gDNA scFv library; pt1-3H/K/L: patient cDNA Fab library. Note: pt1gL library is not available.



**Fig. 2 Percentage of IGHV lineages in the nonimmune and immune gDNA and cDNA**

**libraries.** NIgH: nonimmune gDNA scFv library; NIH: nonimmune cDNA Fab library; pt1-3gH: patient gDNA scFv library; pt1-3H: patient cDNA Fab library.



**Table 1 Number of productive VHs and VKs/VLs with identical putative V(D)J recombinations to known HIV-1 bnmAbs. CD4i mAb X5 and bnmAb m396 against SARS-CoV were included for comparison.**

BnmAbs VHs	IGHV	IGHD	IGHJ	NIgH	pt1gH	pt2gH	pt3gH	NIH	pt2H	pt3H
b12	HV1-3*01	HD2-21*01 F	HJ6*03 F	0	0	0	0	0	0	0
VRC01	HV1-2*02	HD2-21*01	HJ2*01	0	0	0	0	4	0	1
VRC03	HV1-2*02,04; HV1-8*01	HD2-21*01	HJ2*01	0	0	0	0	6	0	4
NIH45-46	HV1-2*02	HD1-26	HJ2*01	0	0	0	0	1	0	1
3BNC60	HV1-2*01	HD3-3	HJ2*01	0	0	0	0	0	0	0
PG9	HV3-33*05	HD1-1*01 F	HJ6*03 F	0	0	0	0	0	0	0
PGT127	HV4-61*05	HD3-16*02	HJ5*02	0	0	0	0	0	0	0
X5	HV1-69*01	HD3-22*01	HJ4*02 F	0	0	1	3	12	2	14
m396	HV1-69*05	HD5-18*01	HJ6*02 F	0	1	0	0	1	0	0
Total no. of trim VH sequences				33,436	23,530	44,027	42,160	80,331	74,053	77,176
BnmAbs VKs/VLs	IGKV / IGLV		IGKJ / IGLJ	NIgK/L	pt1gK	pt2gK/L	pt3gK/L	NIK/L	pt2K/L	pt3K/L
b12	IGKV3-20		IGKJ2	136	3	179	124	1,172	1,093	1,280
VRC01	IGKV3D-15		IGKJ2	0	0	0	0	0	0	0
VRC03	IGKV3-NL5		IGKJ2	0	0	0	0	1	5	0
NIH45-46	IGKV3D-15		IGKJ2	0	0	0	0	0	1	0
3BNC60	IGKV1-33, IGKV1D-33		IGKJ3	0	0	1	0	1	2	0
PG9	IGLV2-14		IGLJ3	181	NA	100	167	381	605	195
PGT127	IGLV2-8		IGLJ2, IGLJ3	90	NA	13	114	483	255	102
X5	IGKV3-20		IGKJ2	136	4	179	124	1,172	1,093	1,280
m396	IGLV3-21		IGLJ1	0	NA	0	0	5	28	19
Total no. of trim VK and VL sequences				23,670	21,254	19,162	17,285	26,902	26,508	27,639



**Table 2 Number of VHs and VKs/VLs that used the same or very similar V-genes and had the same CDR3 length as known HIV-1 bnmAbs. CD4i mAb X5 and bnmAb m396 against SARS-CoV were included for comparison.**

BnmAbs VHs	IGHVs	CDR3 length	NIgH	pt1gH	pt2gH	pt3gH	NIH	pt2H	pt3H
<b>b12</b>	HV1-3*01,02;1-8*02;1-18*01,03	20 AA	3	10	0	0	34	69	58
<b>VRC01</b>	HV1-2 *01-05	14 AA	1	2	0	1	79	122	210
<b>VRC03</b>	HV1-2*02,04,05;1-8*01,02	23 AA	0	2	0	0	8	4	58
<b>NIH45-46</b>	HV1-2*02-05;1-3*01	18 AA	10	17	10	1	47	48	115
<b>3BNC60</b>	HV1-2*01-05	17 AA	0	7	0	0	37	24	227
<b>PG9</b>	HV3-33*01,05,06; &3-30*02,03	30 AA	0	0	0	0	0	0	0
<b>PGT127</b>	HV4-39*03,06,07;4-61*05;4-b*02	25 AA	0	1	0	0	1	2	0
<b>X5</b>	HV1-69*01,05,06,12,13	24 AA	2	3	0	2	3	3	4
<b>m396</b>	HV1-69*01,02,04,05,09	11 AA	5	18	2	7	77	42	38
<b>Total no. of trim VH sequences</b>			33,436	23,530	44,027	42,160	80,331	74,053	77,176
BnmAbs VKs/VLs	IGKV / IGLVs	CDR3 length	NIgK/L	pt1gK	pt2gK/L	pt3gK/L	NIK/L	pt2K/L	pt3K/L
<b>b12</b>	IGKV3-20, 3D-20, 3-NL5, 3D-15	9 AA	177	5	218	159	1,834	1,665	2,117
<b>VRC01</b>	IGKV3-15, 3D-15, 3-7	7 AA	1	0	0	1	0	0	1
<b>VRC03</b>	IGKV3-NL5, 3-20, 3D-20, 3D-15	5 AA	1	0	5	0	7	10	6
<b>NIH45-46</b>	IGKV3-15, 3D-15, 3-7	5 AA	0	0	1	1	1	4	0
<b>3BNC60</b>	IGKV1-33, 1D-33, 1-39, 1D-39	5 AA	0	14	1	0	1	5	0
<b>PG9</b>	IGLV2-14, 2-23	10 AA	377	NA	266	320	675	1,201	298
<b>PGT127</b>	IGLV2-8, IGLV2-11	10 AA	143		26	179	522	343	142
<b>X5</b>	KV3-20, KV3D-20, KV3-NL5, KV3D-7	9 AA	181	5	218	155	1,805	1,655	2,103
<b>m396</b>	IGLV3-21, IGLV3-9	10 AA	9	NA	0	0	61	141	230
<b>Total no. of trim VK and VL sequences</b>			23,670	21,254	19,162	17,285	26,902	26,508	27,639

Supplemental Data File (.doc, .tif, pdf, etc.)

[Click here to download Supplemental Data File \(.doc, .tif, pdf, etc.\): 1-13AIDS\\_gDNA 454\\_supplementary table S1-2.docx](#)